References
- Cardinale F et al. Community-acquired pneumonia in children. Early
Human Development 2013; S49–S52
- Sinaniotis CA. Viral pneumonia in children: incidence and aetiology.
Paediatr Resp Rev 2004; 5:S197–S200
- Talal F and Thomson Anne H. et al. The burden of pneumonia in children
in the developed world. Paediatric Respiratory Reviews 2005; 6;76-82
- Waites K, Talkington D: Mycoplasma pneumoniae and Its Role as a Human
Pathogen. Clin Microbiol Rev 2004; 17:697-728
- Saegeman
V,
Proesmans
M,
Dumke
R. Pediatr Management of macrolide-resistant Mycoplasma pneumoniae
infection. Infect Dis J. 2012; 31(11):1210-1
- Harris M, Clark J et al. British Thoracic Society guidelines for the
management of community acquired pneumonia in children: update 2011.
Thorax 2011; 66:ii1-ii23
- Okazaki N, Narita M, Yamada S et al. Characteristics of
macrolide-resistant mycoplasma pneumoniae strains isolated from
patients and induced with erythromycin in vitro. Microbiol Immunol.
2001; 45:617-620
- Xin D, Mi Z Han X et al. Molecular mechanisms of macrolide resistance
in clinical isolates of mycoplasma pneumoniae from China. Antimicrob
Agents Chemother 2009; 2158-2159
- Liu Y, Ye X, Zhang H et al. Antimicrobial susceptibility of mycoplasma
pneumoniae isolates and molecular analysis on macrolide resistant
strains from shanghai, China. Antimicrob Agents Chemother 2009; 53:
2160-2162
- Zhao F, Liu G, Wu J, Cao B, Tao X, He L, et al. Surveillance of
macrolide-resistant Mycoplasma pneumoniae in Beijing, China, from 2008
to 2012. Antimicrob Agents Chemother. 2013; 57(3):1521–3
- Matsuoka M, Narita M, Okazaki N et al. Characterization and molecular
analysis of macrolide-resistant mycoplasma pneumoniae clinical
isolates obtained in Japan. Antimicrob Agents Chemother 2004;
48:4624-4630
- Morozumi M, Iwata S, Hasegawa K et al. Acute respiratory diseases
study group. Increased macrolide resistance of mycoplasma pneumoniae
in pediatric patients with community acquired pneumonia. Antimicrob
Agents Chemother 2008; 52:348-350
- R. Dumke, H von Baum et al. Occurrence of macrolide-resistant
Mycoplasma pneumoniae strains in Germany. Clin Microbiol Infect 2010;
16:613-616
- Chironna M, Sallustio A, Esposito S, Perulli M, Chinellato I, Di Bari
C, et al. Emergence of macrolide-resistant strains during an outbreak
of Mycoplasma pneumoniae infections in children. J Antimicrob
Chemother. 2011; 66(4):734-7
- Sauteur M Meyer Patrick, Bleisch Barbara et al. Swiss Med Wkly 2014
- Lung C David et al. Rapid Defervescence after Doxycycline Treatment of
Macrolide-Resistant Mycoplasma pneumoniae Associated
Community-Acquired Pneumonia in Children. Ped Infec Dis J 2013; vol
32:12:1396-1399
- Esposito S, Cohen R, Domingo JD et al. Antibiotic therapy for
pediatric community-acquired pneumonia: do we know when, what and for
how long to treat? Pediatr Infect Dis J 2012; 31: e78 – 85
- Principi N, Esposito S. Emerging role of Mycoplasma pneumoniae and
Chlamydia pneumoniae in paediatric respiratory-tract infections.
Lancet Infect Dis 2001; 1:334 – 44
- AliReza E et al. Macrolide- Resistant Mycoplasma pneumoniae in Humans,
Ontario, Canada, 2010–2011. Emerg Infect Dis 2013; vol 19:9
- N. Miyashita, Y Kawai et al. Macrolide-resistant Mycoplasma pneumoniae
in adolescents and community-acquired pneumonia. BMC Infect Dis 2012;
12:126
- Morozumi M, Ito A, Murayama Somay Y et al Assessment of real-time PCR
for diagnosis of Mycoplasma pneumoniae pneumonia in pediatric
patients. Canadian Journal of Microbiology 2006; 52, 2
22. Peuchant O, Ménard A et al. Increased macrolide resistance of
Mycoplasma pneumonia in France directly detected in clinical specimens
by real-time PCR and melting curve analysis. J Antimicrob Chemother 2009
52-58